Citadel Advisors
WST icon

Citadel Advisors’s West Pharmaceutical WST Stock Holding History

Citadel Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.91M Buy
11,600
+400
+4% +$99.5K ﹤0.01% 5329
2025
Q4 		$3.08M Buy
11,200
+3,300
+42% +$903K ﹤0.01% 5106
2025
Q3 		$2.07M Sell
7,900
-17,300
-69% -$4.2M ﹤0.01% 6001
2025
Q2 		$5.51M Sell
25,200
-4,500
-15% -$962K ﹤0.01% 3935
2025
Q1 		$6.65M Buy
29,700
+7,000
+31% +$1.93M ﹤0.01% 3450
2024
Q4 		$7.44M Sell
22,700
-21,800
-49% -$6.86M ﹤0.01% 3359
2024
Q3 		$13.4M Buy
44,500
+7,600
+21% +$2.33M ﹤0.01% 2522
2024
Q2 		$12.2M Sell
36,900
-213,700
-85% -$75.5M ﹤0.01% 2531
2024
Q1 		$99.2M Buy
250,600
+209,400
+508% +$77.5M 0.02% 698
2023
Q4 		$14.5M Buy
41,200
+15,600
+61% +$5.52M ﹤0.01% 2377
2023
Q3 		$9.61M Buy
25,600
+15,600
+156% +$6.03M ﹤0.01% 2730
2023
Q2 		$3.82M Buy
10,000
+5,800
+138% +$2.07M ﹤0.01% 4049
2023
Q1 		$1.46M Sell
4,200
-5,400
-56% -$1.58M ﹤0.01% 5974
2022
Q4 		$2.26M Buy
9,600
+2,500
+35% +$592K ﹤0.01% 5249
2022
Q3 		$1.75M Sell
7,100
-2,000
-22% -$609K ﹤0.01% 5845
2022
Q2 		$2.75M Sell
9,100
-52,200
-85% -$17M ﹤0.01% 4922
2022
Q1 		$25.2M Buy
61,300
+36,700
+149% +$14.4M 0.01% 1726
2021
Q4 		$11.5M Buy
24,600
+4,300
+21% +$1.85M ﹤0.01% 2826
2021
Q3 		$8.62M Buy
20,300
+9,200
+83% +$3.88M ﹤0.01% 3340
2021
Q2 		$3.99M Sell
11,100
-1,900
-15% -$628K ﹤0.01% 4944
2021
Q1 		$3.66M Buy
13,000
+700
+6% +$200K ﹤0.01% 4975
2020
Q4 		$3.48M Buy
12,300
+7,400
+151% +$2.08M ﹤0.01% 4326
2020
Q3 		$1.35M Buy
4,900
+1,600
+48% +$423K ﹤0.01% 5474
2020
Q2 		$750K Buy
3,300
+1,100
+50% +$216K ﹤0.01% 6354
2020
Q1 		$335K Buy
+2,200
New +$339K ﹤0.01% 7137
2019
Q4 		– Sell
-28,400
Closed -$4.03M – 9854
2019
Q3 		$4.03M Buy
28,400
+13,300
+88% +$1.83M ﹤0.01% 3405
2019
Q2 		$1.89M Sell
15,100
-3,500
-19% -$413K ﹤0.01% 4604
2019
Q1 		$2.05M Buy
18,600
+12,400
+200% +$1.29M ﹤0.01% 4419
2018
Q4 		$608K Buy
+6,200
New +$673K ﹤0.01% 6104
2017
Q3 		– Sell
-6,100
Closed -$577K – 8126
2017
Q2 		$577K Buy
6,100
+3,300
+118% +$304K ﹤0.01% 4921
2017
Q1 		$229K Buy
+2,800
New +$234K ﹤0.01% 6314
2015
Q4 		– Sell
-1,000
Closed -$54K – 9266
2015
Q3 		$54K Sell
1,000
-2,600
-72% -$152K ﹤0.01% 7529
2015
Q2 		$209K Buy
3,600
+1,500
+71% +$83.7K ﹤0.01% 6262
2015
Q1 		$126K Buy
+2,100
New +$112K ﹤0.01% 6653
2014
Q4 		– Sell
-1,100
Closed -$49K – 8763
2014
Q3 		$49K Buy
+1,100
New +$46.7K ﹤0.01% 6925
2014
Q2 		– Sell
-200
Closed -$9K – 8350
2014
Q1 		$9K Sell
200
-2,900
-94% -$137K ﹤0.01% 7551
2013
Q4 		$152K Buy
+3,100
New +$145K ﹤0.01% 5272

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's WST Position: Q1 2026 in Review

Citadel Advisors increased its West Pharmaceutical (WST) stake by 32% in Q1 2026, buying an estimated $19.4M and bringing the position to 323,587 shares worth $81.1M. The position accounts for 0.01% of the portfolio, ranked #959.

Citadel Advisors first reported a position in WST in Q2 2013 and has held it in 48 quarters since. The position peaked at $582M in Q3 2023. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Citadel Advisors held 323,587 shares of West Pharmaceutical worth $81.1M as of Q1 2026.
  • Citadel Advisors bought 77,947 West Pharmaceutical shares in Q1 2026, an estimated $19.4M.
  • West Pharmaceutical made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #959 holding.
  • Citadel Advisors first reported a position in West Pharmaceutical in Q2 2013 and has held it in 48 quarters since.
  • Citadel Advisors's West Pharmaceutical position peaked at $582M in Q3 2023.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.